Andrew D. Ashe's Net Worth
$620 Thousand
Who is Andrew D. Ashe?
Andrew D. Ashe does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Verve Therapeutics, Inc., APPLIED GENETIC TECHNOLOGIES CORP, and DYAX CORP.
SEC CIK
Andrew D. Ashe's CIK is 0001573163
Past Insider Trading and Trends
2016 was Andrew D. Ashe's most active year for acquiring shares with 8 total transactions. Andrew D. Ashe's most active month to acquire stocks was the month of July. 2016 was Andrew D. Ashe's most active year for disposing of shares, totalling 16 transactions. Andrew D. Ashe's most active month to dispose stocks was the month of December. 2016 saw Andrew D. Ashe paying a total of $2,106,437.29 for 297,401 shares, this is the most they've acquired in one year. In 2015 Andrew D. Ashe cashed out on 128,540 shares for a total of $1,569,220.25, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Verve Therapeutics, Inc. (VERV) Snapshot price: $5.595
See RemarksAndrew D. Ashe owns 342,509 units of Common Stock which is worth $1,916,337.86. From 2021 to 2024 Andrew D. Ashe acquired a total of 175,787 shares in Verve Therapeutics, Inc. at a cost of $756,396.74.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +28.52% | 76K |
$6.26 | $475,760.00 | 342.51K |
May 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
| +56.11% | 95.79K |
$1.59 | $152,217.14 | 266.51K |
Aug 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 11
| |||
Form 4
| +2.40% | 4K |
$32.10 | $128,419.60 | 170.72K |
Dec 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
APPLIED GENETIC TECHNOLOGIES CORP No price found
General Counsel
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
DYAX CORP No price found
General Counsel & EVPAndrew D. Ashe used to own units in Common Stock but no longer holds any shares there.acquired a total of 446,221 shares in DYAX CORP at a cost of $2,576,705.24, Andrew also disposed a total of 462,971 shares of DYAX CORP equalling to $2,036,472.55.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -331.53K |
—
|
—
|
0
|
Jan 22
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jan 14
| |||
Form 4
| +871.45% | 297.4K |
$7.08 | $2,106,437.29 | 331.53K |
Jan 14
| |||
Form 4
|
—
|
0
|
$13.14 | -$1,380,631.05 | 34.13K |
Scheduled
|
Aug 3
| ||
Form 4
| -6.57% | -2.40K |
$15.50 | -$37,200.00 | 34.13K |
Scheduled
|
Mar 6
| ||
Form 4
| -3.94% | -1.50K |
$15.34 | -$23,010.00 | 36.53K |
Scheduled
|
Feb 26
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 18
| |||
Form 4
| +195.49% | 24K |
$7.68 | -$10,800.00 | 36.28K |
Feb 27 - Mar 3
| |||
Form 4
| -18.15% | -2.72K |
$10.10 | -$27,502.30 | 12.28K |
Scheduled
|
Feb 26
| ||
Form 4
|
—
|
0
|
$2.96 | -$87,061.25 | 15K |
Aug 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||